scholarly journals LBA2_PR Afatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7 (LL7)

2015 ◽  
Vol 26 ◽  
pp. ix161 ◽  
Author(s):  
K. Park ◽  
E.-H. Tan ◽  
L. Zhang ◽  
V. Hirsh ◽  
K. O'Byrne ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Small Cell ◽  
Egfr Mutations ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
Open Label ◽  
Open Label Phase ◽  
First Line Treatment

scholarly journals Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

2017 ◽  
Vol 18 (1) ◽  
pp. 31-41 ◽  
Author(s):  
Matthew D Hellmann ◽  
Naiyer A Rizvi ◽  
Jonathan W Goldman ◽  
Scott N Gettinger ◽  
Hossein Borghaei ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Phase 1 ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
Open Label ◽  
Open Label Phase ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document